Nkarta (NASDAQ:NKTX - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.
Nkarta (NASDAQ:NKTX - Get Free Report) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.06. On average, analysts expect Nkarta to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Nkarta Stock Performance
Shares of Nkarta stock traded up $0.04 during midday trading on Friday, reaching $2.09. 353,339 shares of the company's stock traded hands, compared to its average volume of 1,087,458. The company has a market cap of $148.30 million, a price-to-earnings ratio of -1.11 and a beta of 0.83. Nkarta has a 52 week low of $1.31 and a 52 week high of $8.23. The company's 50 day simple moving average is $1.76 and its 200 day simple moving average is $2.33.
Analyst Ratings Changes
NKTX has been the subject of several recent analyst reports. Stifel Nicolaus decreased their price target on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of Nkarta in a research report on Wednesday, April 9th. Finally, HC Wainwright reissued a "buy" rating and issued a $18.00 price target on shares of Nkarta in a research report on Thursday, March 27th. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $14.86.
Get Our Latest Stock Analysis on NKTX
Nkarta Company Profile
(
Get Free Report)
Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.
Read More
Before you consider Nkarta, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nkarta wasn't on the list.
While Nkarta currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
